| Market cap | $381.19M |
|---|---|
| Enterprise value | N/A |
| Revenue | $162.473M |
|---|---|
| EBITDA | -$148.19 |
| Income | -$166.43 |
| Revenue Q/Q | 62.79% |
| Revenue Y/Y | 20.09% |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 1.06 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 2.35 |
| P/FCF | N/A |
| Price/Book | 2.22 |
| Book/Share | 0.04 |
| Cash/Share | 2.02 |
| FCF yield | -35.61% |
| Volume | 21.428M / 1.498M |
|---|---|
| Relative vol. | 14.31 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 41.67% |
| Est. EPS Q/Q | -26.09% |
| Profit margin | -102.44% |
|---|---|
| Oper. margin | -100.07% |
| Gross margin | 35.72% |
| EBIT margin | -97.64% |
| EBITDA margin | -91.21% |
| Ret. on assets | -53.79% |
|---|---|
| Ret. on equity | 5,286.46% |
| ROIC | -36.43% |
| ROCE | -80.46% |
| Debt/Equity | -5.43 |
|---|---|
| Net debt/EBITDA | -2.89 |
| Current ratio | 2.73 |
| Quick ratio | 2.02 |
| Volatility | 36.11% |
|---|---|
| Beta | 0.00 |
| RSI | 40.65 |
|---|
| Insider ownership | N/A |
|---|---|
| Inst. ownership | N/A |
| Shares outst. | 48.118M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 13.20% |
| Short ratio | 5.24 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Sunday, 4 February 2024
|
|
| NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology | |
Thursday, 1 February 2024
|
|
| NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability | |
Sunday, 7 January 2024
|
|
| NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution | |
Thursday, 4 January 2024
|
|
| NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference | |
Thursday, 16 November 2023
|
|
| Here’s What Led Conestoga Capital Advisors to Sell Nanostring Technologies | |
Thursday, 14 September 2023
|
|
| NanoString to Host Virtual Spatial Genomics Summit September 19 | |
Tuesday, 8 August 2023
|
|
| NanoString to Webcast Presentations from Upcoming Healthcare Conferences | |
Thursday, 3 August 2023
|
|
| NanoString Technologies Releases Operating Results for Second Quarter of 2023 | |
Tuesday, 11 July 2023
|
|
| Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws | |
Friday, 30 June 2023
|
|
| NanoString Reports Inducement Grants Under Nasdaq Listing Rules | |
Thursday, 18 May 2023
|
|
| Why Shares of NanoString Technologies Are Falling Thursday | |
Wednesday, 12 April 2023
|
|
| Investors in NanoString Technologies have unfortunately lost 69% over the last year | |
Thursday, 2 February 2023
|
|
| Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy | |
Thursday, 19 January 2023
|
|
| NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager | |
Sunday, 8 January 2023
|
|
| NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022 | |
Saturday, 31 December 2022
|
|
| NanoString Technologies, Inc. Q3 2022 Earnings Call Transcript | |
Sunday, 13 November 2022
|
|
| Analyst Forecasts Just Became More Bearish On NanoString Technologies, Inc. | |
Thursday, 10 November 2022
|
|
| NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences | |
Monday, 11 July 2022
|
|
| NanoString to Release Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022 | |
Wednesday, 18 May 2022
|
|
| NanoString to Webcast Presentation from the UBS 2022 Global Healthcare Conference | |
Wednesday, 27 April 2022
|
|
| NanoString to Release First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022 | |
Monday, 18 April 2022
|
|
| NanoString Appoints Dr. Teresa Foy to Board of Directors | |
Wednesday, 13 April 2022
|
|
| NanoString stock plunges after revenue warning, but analyst says selloff appears 'way overdone' | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Joseph M Beechem SVP, Research, and Development | Option 6 May 2024 | $28,092 |
| K Thomas Bailey Chief Financial Officer | Option 6 May 2024 | $34,713 |
| Janet George Director | Option 6 May 2024 | $7,815 |
| Dana E. Rollison Director | Option 6 May 2024 | $7,815 |
| Teresa M. Foy Director | Option 6 May 2024 | $8,545 |
| Gregory Norden Director | Option 6 May 2024 | $7,815 |
| Jonathan Todd Garland Chief Commercial Officer | Option 6 May 2024 | $38,000 |
| Charles P Jr Waite Director | Option 6 May 2024 | $7,815 |
| R Bradley Gray President and CEO | Option 6 May 2024 | $117,274 |
| Kirk Malloy Director | Option 6 May 2024 | $7,815 |
| William Young Director | Option 6 May 2024 | $7,815 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| R. Bradley Gray (43) President, Chief Executive Officer, and Director since 2010 | 43 | 2010 | $7,288,840 |
| K. Thomas Bailey (51) Chief Financial Officer since 2018 | 51 | 2018 | $2,108,690 |
| Joseph Beechem (62) Senior Vice President - Research and Development since 2012 | 62 | 2012 | $2,094,840 |
| John Brown (62) Senior Vice President - Sales and Marketing since 2017 | 62 | 2017 | $2,092,500 |
| David Ghesquiere (53) Senior Vice President - Corporate and Business Development since 2013 | 53 | 2013 | $1,455,550 |
| R. Bradley Gray (44) CEO, Pres, and Director | 44 | $1,141,130 | |
| K. Thomas Bailey M.B.A. (52) Chief Financial Officer | 52 | $638,164 | |
| Dr. Joseph M. Beechem (63) Chief Scientific Officer, Sr. VP of R, and Director | 63 | $615,920 | |
| J. Chad Brown (63) Sr. VP of Sales and Marketing | 63 | $612,994 | |
| David W. Ghesquiere (54) Sr. VP of Corp. and Bus. Devel. | 54 | $598,612 | |
| William Young (75) Independent Chairman of the Board since 2010 | 75 | 2010 | $241,462 |
| Gregory Norden (62) Independent Director since 2012 | 62 | 2012 | $212,251 |
| Don Kania (65) Independent Director since 2019 | 65 | 2019 | $208,100 |
| Charles Waite (64) Independent Director since 2004 | 64 | 2004 | $207,479 |
| Elisha Finney (58) Independent Director since 2017 | 58 | 2017 | $207,201 |
| Kirk Malloy (53) Independent Director since 2016 | 53 | 2016 | $195,979 |
| Robert Hershberg (57) Independent Director since 2015 | 57 | 2015 | $194,979 |
| Elizabeth Schneider Ph.D. | |||
| Dr. Philippa Webster Ph.D. | |||
| Dr. Mary Tedd Allen (58) Sr. VP of Strategic Initiatives | 58 | ||
| Kathryn Surace-Smith (62) Sr. VP of HR, Legal Affairs, and Corp. Sec. | 62 | ||
| Douglas S. Farrell | |||
| Mark A. Winham |
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
- Health Care > Biotechnology
- Nanostring Technologies Inc, 530 Fairview Avenue North, Seattle 98109, United States
- 206 378 6266
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 30 Sep 2023 | 30 Jun 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $94.098 | $114.93 | |||
| Short term investments | $3.299 | $3.297 | |||
| Net receivables | $48.352 | $42.982 | |||
| Inventory | $55.159 | $48.849 | |||
| Total current assets | $211.807 | $221.445 | |||
| Long term investments | |||||
| Property, plant & equipment | $59.411 | $63.397 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $62.906 | $67.545 | |||
| Total investments | $3.299 | $3.297 | |||
| Total assets | $274.713 | $288.99 | |||
| Current liabilities | |||||
| Accounts payable | $33.335 | $20.868 | |||
| Deferred revenue | $18.471 | $17.123 | |||
| Short long term debt | $5.578 | $5.44 | |||
| Total current liabilities | $77.532 | $62.433 | |||
| Long term debt | $242.124 | $243.182 | |||
| Total noncurrent liabilities | $247.747 | $248.018 | |||
| Total debt | $247.702 | $248.622 | |||
| Total liabilities | $325.279 | $310.451 | |||
| Stockholders' equity | |||||
| Retained earnings | -$931.613 | -$894.202 | |||
| Other stockholder equity | $0.004 | $0.004 | |||
| Total stockholder equity | -$50.566 | -$21.461 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.148 | $107.068 | ||
| Short term investments | $84.282 | $241.821 | ||
| Net receivables | $31.506 | $40.13 | ||
| Inventory | $43.273 | $31.486 | ||
| Total current assets | $286.774 | $427.62 | ||
| Long term investments | ||||
| Property, plant & equipment | $62.038 | $46.269 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $66.638 | $51.861 | ||
| Total investments | $84.282 | $241.821 | ||
| Total assets | $353.412 | $479.481 | ||
| Current liabilities | ||||
| Accounts payable | $16.619 | $14.283 | ||
| Deferred revenue | $13.342 | $11.001 | ||
| Short long term debt | $5.518 | $4.889 | ||
| Total current liabilities | $58.86 | $52.155 | ||
| Long term debt | $244.984 | $246.837 | ||
| Total noncurrent liabilities | $248.738 | $250.364 | ||
| Total debt | $250.502 | $251.726 | ||
| Total liabilities | $307.598 | $302.519 | ||
| Stockholders' equity | ||||
| Retained earnings | -$809.296 | -$649.753 | ||
| Other stockholder equity | -$0.589 | -$0.318 | ||
| Total stockholder equity | $45.814 | $176.962 | ||
Income statement
| (in millions USD) | 30 Sep 2023 | 30 Jun 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $48.089 | $44.157 | |||
| Cost of revenue | $30.686 | $29.757 | |||
| Gross profit | $17.403 | $14.4 | |||
| Operating activities | |||||
| Research & development | $17.115 | $18.214 | |||
| Selling, general & administrative | $36.755 | $39.076 | |||
| Total operating expenses | $53.87 | $57.29 | |||
| Operating income | -$36.467 | -$42.89 | |||
| Income from continuing operations | |||||
| EBIT | -$35.563 | -$41.574 | |||
| Income tax expense | -$0.049 | $0.205 | |||
| Interest expense | $1.897 | $1.889 | |||
| Net income | |||||
| Net income | -$37.411 | -$43.668 | |||
| Income (for common shares) | -$37.411 | -$43.668 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $127.262 | $145.085 | ||
| Cost of revenue | $65.475 | $68.304 | ||
| Gross profit | $61.787 | $76.781 | ||
| Operating activities | ||||
| Research & development | $70.841 | $69.504 | ||
| Selling, general & administrative | $143.129 | $115.503 | ||
| Total operating expenses | $213.97 | $185.007 | ||
| Operating income | -$152.183 | -$108.226 | ||
| Income from continuing operations | ||||
| EBIT | -$151.691 | -$107.597 | ||
| Income tax expense | $0.317 | $0.167 | ||
| Interest expense | $7.535 | $7.49 | ||
| Net income | ||||
| Net income | -$159.543 | -$115.254 | ||
| Income (for common shares) | -$159.543 | -$115.254 | ||
Cash flows
| (in millions USD) | 30 Sep 2023 | 30 Jun 2023 | |||
|---|---|---|---|---|---|
| Net income | -$37.411 | -$43.668 | |||
| Operating activities | |||||
| Depreciation | $5.074 | $5.006 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $7.44 | $8.436 | |||
| Total cash flows from operations | -$19.699 | -$31.448 | |||
| Investing activities | |||||
| Capital expenditures | -$1.916 | -$5.692 | |||
| Investments | $30 | ||||
| Total cash flows from investing | -$1.916 | $24.308 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.866 | $0.092 | |||
| Net borrowings | -$0.044 | -$0.056 | |||
| Total cash flows from financing | $0.822 | $0.036 | |||
| Effect of exchange rate | -$0.039 | $0.001 | |||
| Change in cash and equivalents | -$20.832 | -$7.103 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Net income | -$159.543 | -$115.254 | ||
| Operating activities | ||||
| Depreciation | $12.205 | $9.321 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.908 | $30.173 | ||
| Total cash flows from operations | -$128.606 | -$90.549 | ||
| Investing activities | ||||
| Capital expenditures | -$23.066 | -$8.647 | ||
| Investments | $155.563 | -$211.575 | ||
| Total cash flows from investing | $132.497 | -$220.222 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.109 | $8.879 | ||
| Net borrowings | -$0.333 | -$0.236 | ||
| Total cash flows from financing | $2.272 | $6.058 | ||
| Effect of exchange rate | -$0.083 | -$0.067 | ||
| Change in cash and equivalents | $6.08 | -$304.78 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Goldman Sachs Group Inc |
-97.28%
|
21,525 | $1,722 |
| 2024 Q1 | Barclays PLC |
-97.28%
|
1,994 | $0 |
| 2024 Q1 | Simplex Trading |
-99.38%
|
200 | $0 |
| 2024 Q1 | Cadence Wealth Management |
+120.67%
|
41,903 | $3,352 |
| 2024 Q1 | Shell Asset Management Co |
-10.04%
|
1,264 | $0 |
| 2023 Q4 | Polar Capital PLC |
Sold out
|
3,975,000 | $2,974,890 |
| 2023 Q4 | Blackrock |
Sold out
|
3,574,938 | $2,675,482 |
| 2023 Q4 | Morgan Stanley |
Sold out
|
2,333,231 | $1,746,190 |
| 2023 Q4 | State Street Corp |
Sold out
|
1,536,756 | $1,150,108 |
| 2023 Q4 | Gsa Capital Partners LL.P. |
Sold out
|
1,279,363 | $957 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Clarus Ventures | 8.39% | 4,036,025 | |
| Polar Capital PLC | 8.26% | 3,975,000 | |
| Blackrock | 7.43% | 3,574,938 | |
| Vanguard Group Inc | 7.42% | 3,569,859 | |
| Fred Alger Management | 5.22% | 2,511,364 | |
| Morgan Stanley | 4.85% | 2,333,231 | |
| D. E. Shaw & Co | 4.41% | 2,120,143 | |
| Acadian Asset Management | 4.16% | 2,003,708 | |
| Prosight Management, L.P. | 4.16% | 2,000,000 | |
| State Street Corp | 3.19% | 1,536,756 |
Sign up